Profound Medical 2025 Q3 Earnings Record Revenue Growth of 87% and Narrowed Net Loss

Profound Medical (PROF) reported its fiscal 2025 Q3 earnings on Nov 14, 2025, with revenue surging 87% year-over-year to $5.29 million and a 14.8% reduction in net losses. The results outperformed analyst expectations and highlighted strategic progress in market expansion.

Revenue

Profound Medical’s total revenue in Q3 2025 reached $5.29 million, reflecting an 86.8% increase compared to $2.83 million in Q3 2024. Recurring non-capital revenue contributed $4.07 million, while capital equipment revenue added $1.22 million. This diversification underscores the company’s growing adoption of its TULSA-PRO platform and related services.

Earnings/Net Income

The company narrowed its net loss to $7.98 million ($0.26 per share) in Q3 2025, a 14.8% improvement from $9.37 million ($0.38 per share) in Q3 2024. The EPS improvement and reduced net loss indicate positive progress despite ongoing losses, which have persisted for six consecutive years.

Post-Earnings Price Action Review

The strategy of buying Profound Medical shares following its revenue growth announcement historically yielded favorable returns over 30 days. This Q3’s 87% revenue surge likely spurred initial investor optimism, aligning with typical market reactions to earnings beats. A 30-day holding period captured post-earnings momentum, though external factors like market volatility or industry news could influence outcomes. However, this backtest assumes rational market behavior and does not account for unforeseen events.

CEO Commentary

Dr. Arun Menawat, CEO, emphasized the company’s trajectory toward “profitable growth,” citing the TULSA-PRO platform’s integration of MRI and AI-driven treatments as a competitive edge. He highlighted strategic initiatives, including 75 TULSA-PRO installations by year-end and expanding into BPH treatment to broaden the total addressable market.

Guidance

The company anticipates maintaining a 70–75% annual revenue growth rate and aims to secure national and regional payer coverage. Future installations of TULSA-PRO systems and expanded market reach in prostate and BPH treatments are expected to drive long-term revenue potential.

Additional News

1. Saudi Distribution Deal: Profound secured an exclusive agreement with Al Faisaliah Medical Systems for TULSA-PRO and Sonalleve technologies in Saudi Arabia, enhancing Middle East market access.

2. Zacks Rating: The stock received a Zacks Rank #3 (Hold), reflecting mixed earnings estimate revisions and a projected in-line performance with the market.

3. Institutional Ownership: Institutional ownership remains at 41.53%, with analysts averaging a $11.31 price target, signaling moderate buy sentiment.